Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research and development of photo dynamic compounds (PDCs) and their associated drug formulations to treat cancer in Canada, the United States, and internationally. More Details
Flawless balance sheet with limited growth.
Share Price & News
How has Theralase Technologies's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: TLT is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: TLT's weekly volatility (12%) has been stable over the past year.
7 Day Return
CA Medical Equipment
1 Year Return
CA Medical Equipment
Return vs Industry: TLT underperformed the Canadian Medical Equipment industry which returned 32.5% over the past year.
Return vs Market: TLT underperformed the Canadian Market which returned 36.9% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Theralase Technologies's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 months ago | Simply Wall StWe're Keeping An Eye On Theralase Technologies' (CVE:TLT) Cash Burn Rate
7 months ago | Simply Wall StHere's Why We're Watching Theralase Technologies' (CVE:TLT) Cash Burn Situation
11 months ago | Simply Wall StThe Theralase Technologies (CVE:TLT) Share Price Is Down 47% So Some Shareholders Are Getting Worried
Is Theralase Technologies undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate TLT's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate TLT's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: TLT is unprofitable, so we can't compare its PE Ratio to the North American Medical Equipment industry average.
PE vs Market: TLT is unprofitable, so we can't compare its PE Ratio to the Canadian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate TLT's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: TLT is good value based on its PB Ratio (4.7x) compared to the CA Medical Equipment industry average (5.5x).
How is Theralase Technologies forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TLT is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: TLT is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: TLT is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: TLT's revenue (71.3% per year) is forecast to grow faster than the Canadian market (6.7% per year).
High Growth Revenue: TLT's revenue (71.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: TLT is forecast to be unprofitable in 3 years.
How has Theralase Technologies performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: TLT is currently unprofitable.
Growing Profit Margin: TLT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: TLT is unprofitable, and losses have increased over the past 5 years at a rate of 5.8% per year.
Accelerating Growth: Unable to compare TLT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TLT is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (26.7%).
Return on Equity
High ROE: TLT has a negative Return on Equity (-61.1%), as it is currently unprofitable.
How is Theralase Technologies's financial position?
Financial Position Analysis
Short Term Liabilities: TLT's short term assets (CA$8.9M) exceed its short term liabilities (CA$821.4K).
Long Term Liabilities: TLT's short term assets (CA$8.9M) exceed its long term liabilities (CA$35.7K).
Debt to Equity History and Analysis
Debt Level: TLT is debt free.
Reducing Debt: TLT had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: TLT has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: TLT has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of 2.8% each year.
What is Theralase Technologies's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate TLT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate TLT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if TLT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if TLT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of TLT's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dr. Shawn Shirazi, Ph.D., M.Sc., B.Sc., is Chief Executive Officer at Theralase Technologies Inc. since October 31, 2019 and served as its Chief Executive Officer of Drug since February 25, 2019 until Octo...
CEO Compensation Analysis
Compensation vs Market: Shawn's total compensation ($USD287.25K) is above average for companies of similar size in the Canadian market ($USD156.55K).
Compensation vs Earnings: Insufficient data to compare Shawn's compensation with company performance.
Experienced Management: TLT's management team is seasoned and experienced (11.4 years average tenure).
Experienced Board: TLT's board of directors are considered experienced (6.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: TLT insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Theralase Technologies Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Theralase Technologies Inc.
- Ticker: TLT
- Exchange: TSXV
- Founded: 1995
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: CA$42.898m
- Shares outstanding: 204.28m
- Website: https://www.theralase.com
Number of Employees
- Theralase Technologies Inc.
- 41 Hollinger Road
- M4B 3G4
Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research and development of photo dynamic compounds (PDCs) and their associated drug formulations to treat cancer in Can...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/10 22:31|
|End of Day Share Price||2021/05/10 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.